Aytu BioPharma, Inc. develops and commercializes prescription medicines focused on complex central nervous system diseases. Its recurring company updates center on EXXUA (gepirone) extended-release tablets, an FDA-approved selective serotonin 5HT1a receptor agonist for major depressive disorder in adults, along with its ADHD products and legacy pediatric portfolio.
News from Aytu also covers operational and financial results, commercial launch activity, retail and Aytu RxConnect patient-access distribution, investor presentations, and product-level clinical and safety information for EXXUA. The company is a Nasdaq-listed specialty pharmaceutical issuer with prescription products sold through commercial distribution channels.
Aytu BioPharma (AYTU) reported fiscal 2026 net revenue of $57.6 million, down 13.3% from $66.4 million in fiscal 2025, and a net loss of ($14.3) million.
EXXUA, launched in mid-January 2026, generated $6.6 million in fiscal 2026 net revenue, including $3.9 million in Q4, Aytu’s first full launch quarter. Q4 net revenue rose 6.4% year over year to $16.1 million, with ADHD Portfolio revenue at $10.4 million and Pediatric Portfolio revenue at $1.8 million. Full-year ADHD revenue declined to $45.8 million from $57.6 million, and Pediatric revenue fell to $5.1 million from $8.8 million, reflecting commercial prioritization of EXXUA and generic competition.
Fiscal 2026 gross profit was $36.8 million (64.0% margin), and Adjusted EBITDA was ($3.7) million versus $9.2 million in 2025. Q4 net loss was approximately break‑even and Adjusted EBITDA was $0.5 million. Cash and cash equivalents were $26.3 million at June 30, 2026. Reclassification of certain warrants reduced derivative warrant liabilities by $26.4 million and increased stockholders’ equity to $35.3 million.
Aytu BioPharma (AYTU) will report fiscal 2026 full year and fourth quarter operational and financial results after market close on Tuesday, September 22, 2026.
The company will host a conference call and webcast the same day at 4:30 p.m. Eastern time, including a question and answer session. U.S. participants can dial (888) 506-0062 and international participants can dial +1 (973) 528-0011, using access code 504506. A live and archived webcast will be available at the provided Webcaster link and in the Investors section of Aytu’s website under Events & Presentations. A teleconference replay will be accessible until October 6, 2026, using replay access code 54094 at the listed U.S. and international numbers.
Aytu BioPharma (Nasdaq: AYTU) will participate in a Fireside Q&A at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
Management will also host in-person 1x1 investor meetings June 17–18, 2026.
Aytu BioPharma (Nasdaq: AYTU), a pharmaceutical company focused on innovative medicines for complex central nervous system diseases, will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026.
The virtual webcast begins at 9:15 a.m. ET, with replay available on the conference site and Aytu’s investor relations webpage. Management will also host virtual one-on-one meetings with investors during the event.
Aytu BioPharma (Nasdaq: AYTU) reported fiscal 2026 Q3 net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million. Adjusted EBITDA was $(2.8) million.
EXXUA generated $2.4 million net revenue in its early launch, with more than 1,300 prescriptions from over 450 prescribers and over 3,200 units sold. ADHD and Pediatric portfolio revenues declined to $9.1 million and $0.9 million, respectively.
Gross profit was $7.6 million (61% margin). Cash was $26.7 million at March 31, 2026. A warrant amendment reduced derivative warrant liabilities by $26.4 million, increasing stockholders’ equity to $35.1 million.
Aytu BioPharma (Nasdaq: AYTU) will report operational and financial results for its fiscal 2026 third quarter after market close on Wednesday, May 13, 2026. A conference call and webcast to review results is scheduled the same day at 4:30 p.m. ET.
Dial-in access, a live webcast link, and a teleconference replay through May 27, 2026, are available for investors and analysts.
Aytu (Nasdaq: AYTU) reported Q2 fiscal 2026 net revenue of $15.2M, adjusted EBITDA of $(0.8)M, and a $30.0M cash balance at December 31, 2025. The company launched EXXUA (gepirone) in mid-December 2025 as its commercial centerpiece targeting the >$22B U.S. MDD market.
Q2 results included a $10.6M net loss (driven by an $8.2M derivative warrant liability loss), initial EXXUA stocking revenue of $0.2M, and gross margin of 63%.
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 second quarter operational and financial results after market close on Tuesday, February 3, 2026. The company will host a conference call and live webcast the same day at 4:30 p.m. Eastern time followed by a Q&A session.
Call-in numbers: (888) 506-0062 (U.S.) and +1 (973) 528-0011 (international) using participant access code 567381. The webcast will be available live and archived at the provided webcast link and on the Investors section of the company website under Events & Presentations. A teleconference replay will be available through February 17, 2026 at (877) 481-4010 (U.S.) or +1 (919) 882-2331 (international) using replay access code 53322.
Aytu BioPharma (Nasdaq:AYTU) held Investor Day on January 20, 2026 focused on EXXUA (gepirone) ER, the first FDA‑approved 5HT1a agonist for major depressive disorder (MDD) that launched commercially on December 15, 2025. Management reviewed pivotal Phase 3 results showing statistically significant HAM‑D17 improvement versus placebo (placebo‑subtracted differences of −2.47 and −2.45 at Week 8) and safety data from ~1,976 MDD patients. Company highlighted market opportunity (US MDD market > $22B), full national distribution, early prescription uptake, expected EXXUA gross margin of 66–68%, and key commercialization economics including a 28% base royalty and upfront payments tied to Fabre‑Kramer agreement.
Aytu BioPharma (Nasdaq:AYTU) launched EXXUA (gepirone) nationwide on January 20, 2026, following completion of launch training. EXXUA is the first FDA‑approved selective 5‑HT1A agonist for treatment of major depressive disorder in adults and is available through retail and participating Aytu RxConnect pharmacies.
The company positions EXXUA as a once‑daily monotherapy that selectively targets 5‑HT1A receptors while minimizing activity at serotonin receptors tied to sexual dysfunction and weight gain, side effects that the release says commonly drive treatment discontinuation.